Table 4.
Vaccine formulations prepared to test the potency of dry powder rPA vaccines.
Groups | rPA Dose (μg) |
Route | Adjuvant | |
---|---|---|---|---|
1 | liquid, rPA alone | 30 | Nasal | NONE |
2 | liquid, rPA and C48/80 | 30 | Nasal | C48/80, 120 μg |
3 | Powder (prepared Aug.09) | 30 | Nasal | C48/80, 120 μg |
4 | Powder (prepared Sep.07) | 30 | Nasal | C48/80, 120 μg |
5 | liquid, IM | 30 | IM | C48/80, 120 μg |